(Reuters) – U.S. drugmaker Pfizer Inc and its German partner BioNTech SE said on Thursday they have started an early-stage study to evaluate their combination vaccine targeting COVID-19 and influenza.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Savio D’Souza)
